NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend ivosidenib (TIBSOVO®) in R/R AML with an IDH1 mutation1
My Agios | Home

myAgios™ Patient Support Services is a program that helps with access and financial assistance

myAgios™ Patient Support Services for TIBSOVO® include:

  • Support with insurance coverage and reimbursement
  • Financial assistance and coverage support programs to help patients with access to TIBSOVO
  • Prescription fulfillment through our network of specialty pharmacies and distributors
To enroll patients in myAgios, visit myagios.com or call 1-844-409-1141, Monday through Friday, 8 AM to 6 PM ET.

Ordering and distribution network

National Drug Code (NDC)

NDCs Dosage strength Description
10-digit code: 71334-100-01
11-digit code: 71334-0100-01
250 mg/tablet 250-mg tablet: Blue oval-shaped film-coated tablet debossed “IVO” on one side and “250” on the other side
The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

Product information

How TIBSOVO is supplied: 250-mg tablets, supplied in 60-count bottles (30-day supply) with a desiccant canister

Storage: Store at 20º to 25º C (68º F to 77º F)

TIBSOVO® Bottle

Distribution network for TIBSOVO

TIBSOVO is only available through our specialty distributors and network specialty pharmacies.

Specialty distributors: TIBSOVO is available through specialty distributors for shipment directly to office- or hospital-based pharmacies.
Network specialty pharmacies: TIBSOVO ships directly from the specialty pharmacy to your patient’s home or preferred location.

Resources for your patients and their caregivers

These resources may be useful to patients and caregivers throughout treatment with TIBSOVO

Resources for you and your practice

 

INDICATION

TIBSOVO® (ivosidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Indication & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.